Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Wilson Website

Wyndham Wilson, M.D., Ph.D.

Selected Publications

1)  Wilson WH, Pittaluga S, Nicolae A, Camphausen K, Shovlin M, Steinberg SM, Roschewski M, Staudt LM, Jaffe ES, Dunleavy K.
A prospective study of mediastinal gray zone lymphoma.
Blood. [Epub ahead of print], 2014.
2)  Parilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL.
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
Blood. [Epub ahead of print], 2014.
3)  Dunleavy K, Wilson WH.
Appropriate management of molecular subtypes of diffuse large B-cell lymphoma.
Oncology (Williston Park, N.Y.). 28: 326-34, 2014.
4)  Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
Haematologica. [Epub ahead of print], 2014.
5)  Roschewski M, Staudt LM, Wilson WH.
Diffuse large B-cell lymphoma-treatment approaches in the molecular era.
Nat Rev Clin Oncol. 11: 12-23, 2014.
6)  Mughal TI, Girnius S, Rosen ST, Kumar S, Wiestner A, Abdel-Wahab O, Kiladjian J, Wilson WH, Van Etten RA.
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Leuk. Lymphoma. [Epub ahead of print], 2014.
7)  Roschewski M, Manasanch EE, Wilson WH.
Management of heavy chain diseases: the challenges of biologic heterogeneity.
Oncology. 28: 63-5, 2014.
8)  Roschewski M, Dunleavy K, Wilson WH.
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Leuk. Lymphoma. [Epub ahead of print], 2014.
9)  Kawabata S, Mercado-Matos JR, Hollander MC, Donahue D, Wilson W, Regales L, Butaney M, Pao W, Wong KK, Jänne PA, Dennis PA.
Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.
Cell Rep. 7: 1824-32, 2014.
10)  Dogan I, Kawabata S, Bergbower E, Gills JJ, Ekmekci A, Wilson W, Rudin CM, Dennis PA.
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Lung Cancer. 85: 1-6, 2014.
11)  Tsai HT, Pfeiffer RM, Warren J, Wilson W, Landgren O.
The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma.
Leuk. Lymphoma. 1-6, 2014.
12)  Bax HI, Freeman AF, Anderson VL, Vesterhus P, Laerum D, Pittaluga S, Wilson WH, Holland SM.
B-cell lymphoma in a patient with complete interferon gamma receptor 1 deficiency.
J. Clin. Immunol. 33: 1062-6, 2013.
13)  Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ.
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
Clin. Cancer Res. 19: 6313-21, 2013.
14)  Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M.
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
Clin. Cancer Res. 19: 6873-81, 2013.
15)  Kantarjian H, Wilson W, Ravandi F, Estey E.
Decitabine in older adults with acute myeloid leukemia: why was the dream broken?.
J. Clin. Oncol. 31: 1795-6, 2013.
16)  Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH.
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
N. Engl. J. Med. 368: 1408-16, 2013.
17)  Dunleavy K, Wilson WH.
Implications of the shifting pathobiology of AIDS-related lymphoma.
J. Natl. Cancer Inst. 105: 1170-1, 2013.
18)  Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P, Giné E, Pinyol M, Royo C, Nadeu F, Conde L, Juan M, Clot G, Vizán P, Di Croce L, Puente DA, López-Guerra M, Moros A, Roue G, Aymerich M, Villamor N, Colomo L, Martínez A, Valera A, Martín-Subero JI, Amador V, Hernández L, Rozman M, Enjuanes A, Forcada P, Muntañola A, Hartmann EM, Calasanz MJ, Rosenwald A, Ott G, Hernández-Rivas JM, Klapper W, Siebert R, Wiestner A, Wilson WH, Colomer D, López-Guillermo A, López-Otín C, Puente XS, Campo E.
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110: 18250-5, 2013.
19)  Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, Widemann B, Staudt LM, Jaffe ES, Little RF, Wilson WH.
Low-intensity therapy in adults with Burkitt"s lymphoma.
N. Engl. J. Med. 369: 1915-25, 2013.
20)  Navarro A, Clot G, Prieto M, Royo C, Vegliante MC, Amador V, Hartmann E, Salaverria I, Beà S, Martín-Subero JI, Rosenwald A, Ott G, Wiestner A, Wilson WH, Campo E, Hernández L.
microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics.
Clin. Cancer Res. 19: 3121-9, 2013.
21)  Mo CC, Njuguna N, Beum PV, Lindorfer MA, Vire B, Lee E, Marti G, Wilson WH, Taylor RP, Wiestner A.
Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.
Haematologica. 98: 1259-63, 2013.
22)  Wilson WH, Schenkein DP, Jernigan CL, Woodcock J, Schilsky RL.
Reevaluating the accelerated approval process for oncology drugs.
Clin. Cancer Res. 19: 2804-9, 2013.
23)  Lai C, Wilson W.
T-cell lymphoma.
Best Pract Res Clin Haematol. 26: 1, 2013.
24)  Wilson WH, Grant C, Dunleavy K.
Therapy in primary mediastinal B-cell lymphoma.
N. Engl. J. Med. 369: 283-4, 2013.
25)  Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA.
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
Blood. 122: 3251-62, 2013.
26)  Wilson WH.
Treatment strategies for aggressive lymphomas: what works?.
Hematology Am Soc Hematol Educ Program. 2013: 584-90, 2013.
27)  Dunleavy K, Grant C, Wilson WH.
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.
Ther Adv Hematol. 4: 43-57, 2013.
28)  Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED.
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Haematologica. 97: 758-65, 2012.
29)  Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Blood. 119: 2709-20, 2012.
30)  Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Bcl-2 level as a biomarker for 13q14 deletion in CLL.
Cytometry B Clin Cytom. 84: 237-47, 2012.
31)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Combined normal donor and CLL: Single tube ZAP-70 analysis.
Cytometry B Clin Cytom. 82: 67-77, 2012.
32)  Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ, Wilson WH, Brown JR, Letai A.
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia.
Blood. 120: 3501-9, 2012.
33)  Roschewski M, Dunleavy K, Wilson WH.
Diffuse large B cell lymphoma: molecular targeted therapy.
Int. J. Hematol. 96: 552-61, 2012.
34)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
35)  Roschewski M, Wilson WH.
EBV-associated lymphomas in adults.
Best Pract Res Clin Haematol. 25: 75-89, 2012.
36)  Dunleavy K, Grant C, Eberle FC, Pittaluga S, Jaffe ES, Wilson WH.
Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large B-Cell Lymphoma?.
Curr Hematol Malig Rep. 7: 241-7, 2012.
37)  Dunleavy K, Wilson WH.
How I treat HIV-associated lymphoma.
Blood. 119: 3245-55, 2012.
38)  Roschewski M, Wilson WH.
Lymphomatoid granulomatosis.
Cancer J. 18: 469-74, 2012.
39)  Dunleavy K, Roschewski M, Wilson WH.
Lymphomatoid Granulomatosis and Other Epstein-Barr Virus Associated Lymphoproliferative Processes.
Curr Hematol Malig Rep. 7: 208-15, 2012.
40)  Eberle FC, Song JY, Xi L, Raffeld M, Harris NL, Wilson WH, Pittaluga S, Jaffe ES.
Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Am. J. Surg. Pathol. 36: 716-25, 2012.
41)  Royo C, Navarro A, Clot G, Salaverria I, Giné E, Jares P, Colomer D, Wiestner A, Wilson WH, Vegliante MC, Fernandez V, Hartmann EM, Trim N, Erber WN, Swerdlow SH, Klapper W, Dyer MJ, Vargas-Pabón M, Ott G, Rosenwald A, Siebert R, López-Guillermo A, Campo E, Beà S.
Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.
Leukemia. 26: 1895-8, 2012.
42)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
43)  Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C.
Targeting malignant B cells with an immunotoxin against ROR1.
mAbs. 4, 2012.
44)  Savan R, McFarland AP, Reynolds DA, Feigenbaum L, Ramakrishnan K, Karwan M, Shirota H, Klinman DM, Dunleavy K, Pittaluga S, Anderson SK, Donnelly RP, Wilson WH, Young HA.
A novel role for IL-22R1 as a driver of inflammation.
Blood. 117: 575-84, 2011.
45)  Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, Dunleavy KM, Wilson WH, Staudt LM, Wiestner A.
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Blood. 117: 542-52, 2011.
46)  Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE.
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
Blood. 117: 5835-49, 2011.
47)  Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, Dunleavy K, Pittaluga S, Jaffe ES.
Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.
Am. J. Surg. Pathol. 35: 767-72, 2011.
48)  Dunleavy K, Wilson WH.
Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma.
Clin. Cancer Res. 17: 7505-7, 2011.
49)  Eberle FC, Salaverria I, Steidl C, Summers TA, Pittaluga S, Neriah SB, Rodriguez-Canales J, Xi L, Ylaya K, Liewehr D, Dunleavy K, Wilson WH, Hewitt SM, Raffeld M, Gascoyne RD, Siebert R, Jaffe ES.
Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations.
Mod Pathol. 24: 1586-97, 2011.
50)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation.
Cytometry B Clin Cytom. 80: 309-17, 2011.
51)  Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH.
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
Leuk. Lymphoma. 52: 24-33, 2011.
52)  Degheidy HA, Venzon DJ, Farooqui MZ, Abbasi F, Arthur DC, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE.
Methodological comparison of two anti-ZAP-70 antibodies.
Cytometry B Clin Cytom. 80: 300-8, 2011.
53)  Eberle FC, Rodriguez-Canales J, Wei L, Hanson JC, Killian JK, Sun HW, Adams LG, Hewitt SM, Wilson WH, Pittaluga S, Meltzer PS, Staudt LM, Emmert-Buck MR, Jaffe ES.
Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.
Haematologica. 96: 558-66, 2011.
54)  Lu GL, Stevenson RJ, Chang JY, Brothers PJ, Ware DC, Wilson WR, Denny WA, Tercel M.
N-alkylated cyclen cobalt(III) complexes of 1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ol DNA alkylating agent as hypoxia-activated prodrugs.
Bioorg. Med. Chem. 19: 4861-7, 2011.
55)  Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA, Jaffe ES.
NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series.
Blood. 117: 1447-52, 2011.
56)  Marti GE, Stetler-Stevenson M, Grant ND, White T, Figg WD, Tohnya T, Jaffe ES, Dunleavy K, Janik JE, Steinberg SM, Wilson WH.
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
Leukemia & lymphoma. 2011.
57)  Grant C, Dunleavy K, Eberle FC, Pittaluga S, Wilson WH, Jaffe ES.
Primary Mediastinal Large B-Cell Lymphoma, Classic Hodgkin Lymphoma Presenting in the Mediastinum, and Mediastinal Gray Zone Lymphoma: What is the Oncologist To Do?.
Curr Hematol Malig Rep. 6: 157-63, 2011.
58)  Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, JJingo C, Huang X, Henning SA, Wilson WH, Walsh TJ.
Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
Mycoses. 54: e877-9, 2011.
59)  Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011.
60)  Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L, Raghavachari N, Liu P, McCoy JP, Raffeld M, Stetler-Stevenson M, Yuan C, Sherry R, Arthur DC, Maric I, White T, Marti GE, Munson P, Wilson WH, Wiestner A.
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Blood. 117: 563-74, 2011.
61)  Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Clin. Cancer Res. 17: 5101-12, 2011.
62)  Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DN, Lanier BJ, Morgan RA, Rosenberg SA.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19.
Blood. [Epub ahead of print], 2010.
In Press. [Journal]
63)  Roschewski M, Wilson WH.
Biology and management of rare primary extranodal T-cell lymphomas.
Oncology. 24: 94-100, 2010.
64)  Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature. 463: 88-92, 2010.
65)  Landgren O, Goedert JJ, Rabkin CS, Wilson WH, Dunleavy K, Kyle RA, Katzmann JA, Rajkumar SV, Engels EA.
Circulating serum free light chains as predictive markers of AIDS-related lymphoma.
J. Clin. Oncol. 28: 773-9, 2010.
66)  Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A, Yu Y, Remache Y, Weniger MA, Rafiq S, Suh KS, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy N, Kahl BS, Byrd JC, Wiestner A, Melnick A, Parekh S.
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.
Blood. 116: 1025-34, 2010.
67)  Moriyama B, Henning SA, Childs R, Holland SM, Anderson VL, Morris JC, Wilson WH, Drusano GL, Walsh TJ.
High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
Ann Pharmacother. 44: 929-35, 2010.
68)  Williams ME, Dreyling MH, Kahl BS, Leonard JP, O'Connor OA, Press OW, Wilson WH.
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop.
Leuk. Lymphoma. 51: 390-8, 2010.
69)  Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA.
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Lancet Oncol. 11: 1149-59, 2010.
70)  Grant C, Wilson WH, Dunleavy K.
Neutropenia associated with rituximab therapy.
Curr. Opin. Hematol. 2010.
71)  Dunleavy K, Piekarz RL, Zain J, Janik JE, Wilson WH, O'Connor OA, Bates SE.
New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies.
Clin. Cancer Res. 16: 5608-17, 2010.
72)  Shao H, Xi L, Raffeld M, Pittaluga S, Dunleavy K, Wilson WH, Spector N, Milito C, Morais JC, Jaffe ES.
Nodal and extranodal plasmacytomas expressing immunoglobulin a: an indolent lymphoproliferative disorder with a low risk of clinical progression.
Am. J. Surg. Pathol. 34: 1425-35, 2010.
73)  Tay K, Dunleavy K, Wilson WH.
Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.
Blood Rev. 24: 69-82, 2010.
74)  Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O'Connor OA.
Novel disease targets and management approaches for diffuse large B-cell lymphoma.
Leuk Lymphoma. 51: 1-10, 2010.
75)  Dunleavy K, Tay K, Wilson WH.
Rituximab-associated neutropenia.
Semin. Hematol. 47: 180-6, 2010.
76)  Dunleavy K, Wilson WH.
Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma.
J. Clin. Oncol. 28: e260; author reply e261-2, 2010.
77)  Dunleavy K, Wilson WH.
Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
Leuk. Lymphoma. 51: 1-2, 2010.
78)  Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, Steinberg SM, Yarchoan R, Jaffe ES, Wilson WH.
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Blood. 115: 3017-24, 2010.
79)  Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH.
The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.
Leuk Lymphoma. 51: 28-33, 2010.
80)  Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, Wilson WH, Rosenberg SA.
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
J. Immunother. 32: 689-702, 2009.
81)  Chamberlain MC, Glantz M, Groves MD, Wilson WH.
Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment.
Semin. Oncol. 36: S35-45, 2009.
82)  Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Blood. 113: 6069-76, 2009.
83)  Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O.
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden.
Haematologica. 94: 1259-65, 2009.
84)  Aue G, Njuguna N, Tian X, Soto S, Hughes T, Vire B, Keyvanfar K, Gibellini F, Valdez J, Boss C, Samsel L, McCoy JP, Wilson WH, Pittaluga S, Wiestner A.
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Haematologica. 94: 1266-73, 2009.
85)  Rizzo K, Stetler-Stevenson M, Wilson W, Yuan CM.
Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.
Cytometry B Clin Cytom. 76: 142-9, 2009.
86)  Jiang L, Abati AD, Wilson W, Stetler-Stevenson M, Yuan C.
Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up.
Int J Clin Exp Pathol. 3: 110-6, 2009.
87)  Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I.
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
J. Clin. Oncol. 27: 2983-90, 2009.
88)  Landgren O, Dunleavy K, Wilson WH.
Re: Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
J. Natl. Cancer Inst. 101: 1287-8; author reply 1289-90, 2009.
89)  Tay K, Dunleavy K, Wilson WH.
Targeting HLA-DR.
Leuk. Lymphoma. 50: 1911-3, 2009.
90)  Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, Jasper GA, Stetler-Stevenson M.
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Br. J. Haematol. 145: 173-9, 2009.
91)  O'Mahony D, Peikarz RL, Bandettini WP, Arai AE, Wilson WH, Bates SE.
Cardiac involvement with lymphoma: a review of the literature.
Clin Lymphoma Myeloma. 8: 249-52, 2008.
92)  Shanti RM, Torres-Cabala CA, Jaffe ES, Wilson WH, Brahim JS.
Lymphomatoid granulomatosis with involvement of the hard palate: a case report.
J. Oral Maxillofac. Surg. 66: 2161-3, 2008.
93)  Hwang ST, Janik JE, Jaffe ES, Wilson WH.
Mycosis fungoides and Sezary syndrome.
Lancet. 371: 945-57, 2008.
94)  Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE.
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
J. Clin. Oncol. 26: 2717-24, 2008.
95)  Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM.
Stromal gene signatures in large-B-cell lymphomas.
N. Engl. J. Med. 359: 2313-23, 2008.
96)  Young KH, Leroy K, Moller MB, Colleoni GW, Sanchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC.
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Blood. 112: 3088-98, 2008.
97)  Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A, Rader C.
Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.
Clin. Cancer Res. 14: 396-404, 2008.
98)  O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE.
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
Clin. Cancer Res. 13: 958-64, 2007.
99)  Dunleavy K, Wilson WH, Jaffe ES.
Angioimmunoblastic T cell lymphoma: pathobiological insights and clinical implications.
Curr. Opin. Hematol. 14: 348-53, 2007.
100)  Dunleavy K, Wilson WH.
Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy.
Leuk. Lymphoma. 48: 449-51, 2007.
101)  Dunleavy K, Davis RE, Landgren O, Staudt LM, Wilson WH.
BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?.
Blood. 109: 843-4; discussion 844-5, 2007.
102)  Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I.
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma.
Leukemia. 21: 169-74, 2007.
103)  Kelloff GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, Larson SM, Kostakoglu L, Daube-Witherspoon M, Gastonis C, Siegel BA, Shankar LK, Lee DB, Higley HR, Sigman CC, Carucci D, Timko D, Degennaro LJ, Sigal E, Barker A, Woodcock J.
FDG-PET Lymphoma Demonstration Project Invitational Workshop.
Academic radiology. 14: 330-9, 2007.
104)  Wilson WH.
International consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia.
Cytometry. Part B, Clinical cytometry. 72 Suppl 1: S2, 2007.
105)  Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM.
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.
Blood. 109: 4599-606, 2007.
106)  Dunleavy K, Staudt LM, Wilson WH.
The BCL-2 biomarker in the era of molecular diagnosis of diffuse large B-cell lymphoma.
Leuk. Lymphoma. 48: 1061-3, 2007.
107)  Bernstein WB, Little RF, Wilson WH, Yarchoan R.
Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
Int. J. Hematol. 84: 3-11, 2006.
108)  Schinstine M, Filie AC, Wilson W, Stetler-Stevenson M, Abati A.
Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious.
Cancer. 108: 157-62, 2006.
109)  Wilson WH.
Drug resistance in diffuse large B-cell lymphoma.
Semin. Hematol. 43: 230-9, 2006.
110)  Rao VK, Carrasquillo JA, Dale JK, Bacharach SL, Whatley M, Dugan F, Tretler J, Fleisher T, Puck JM, Wilson W, Jaffe ES, Avila N, Chen CC, Straus SE.
Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS).
Am. J. Hematol. 81: 81-5, 2006.
111)  Nussenblatt RB, Chan CC, Wilson WH, Hochman J, Gottesman M.
International Central Nervous System and Ocular Lymphoma Workshop: recommendations for the future.
Ocul. Immunol. Inflamm. 14: 139-44, 2006.
112)  Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM.
Molecular diagnosis of Burkitt's lymphoma.
N. Engl. J. Med. 354: 2431-42, 2006.
113)  Dunleavy K, Wilson WH.
Primary intraocular lymphoma: current and future perspectives.
Leuk. Lymphoma. 47: 1726-7, 2006.
114)  Sudheendra D, Barth MM, Hegde U, Wilson WH, Wood BJ.
Radiofrequency ablation of lymphoma.
Blood. 107: 1624-6, 2006.
115)  Dunleavy K, Wilson WH, Kaplan LD.
The case for rituximab in AIDS-related lymphoma.
Blood. 107: 3014-5, 2006.
116)  Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P, Rosenberg J, Grillo-Lopez AJ, Wilson WH, Robinson MR.
The pharmacokinetics of rituximab following an intravitreal injection.
Exp. Eye Res. 82: 760-6, 2006.
117)  Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, White T, Wright G, Kwak L, Gress R, Tosato G, Wilson WH.
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.
Blood. 106: 795-802, 2005.
118)  Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, Chiorazzi M, Iqbal J, Gesk S, Siebert R, De Jong D, Jaffe ES, Wilson WH, Delabie J, Ott G, Dave BJ, Sanger WG, Smith LM, Rimsza L, Braziel RM, Müller-Hermelink HK, Campo E, Gascoyne RD, Staudt LM, Chan WC.
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.
Blood. 106: 4315-21, 2005.
119)  Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A.
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.
Blood. 106: 3183-90, 2005.
120)  Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR.
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
Biol. Blood Marrow Transplant. 11: 593-9, 2005.
121)  Ahmad E, Kingma DW, Jaffe ES, Schrager JA, Janik J, Wilson W, Stetler-Stevenson M.
Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow.
Cytometry. Part B, Clinical cytometry. 67: 6-12, 2005.
122)  Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH.
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.
Blood. 105: 496-502, 2005.
123)  Patsalides AD, Atac G, Hedge U, Janik J, Grant N, Jaffe ES, Dwyer A, Patronas NJ, Wilson WH.
Lymphomatoid granulomatosis: abnormalities of the brain at MR imaging.
Radiology. 237: 265-73, 2005.
124)  Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I.
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
J. Clin. Oncol. 23: 6719-29, 2005.
125)  Neelapu SS, Kwak LW, Kobrin CB, Reynolds CW, Janik JE, Dunleavy K, White T, Harvey L, Pennington R, Stetler-Stevenson M, Jaffe ES, Steinberg SM, Gress R, Hakim F, Wilson WH.
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
Nat. Med. 11: 986-91, 2005.
126)  Murdock J, Jaffe ES, Wilson WH, McManus DT, Alexander HD, Morris TC.
Aggressive natural killer cell leukemia/lymphoma: case report, use of telesynergy and review of the literature.
Leuk. Lymphoma. 45: 1269-73, 2004.
127)  Lunning MA, Zenger VE, Dreyfuss R, Stetler-Stevenson M, Rick ME, White TA, Wilson WH, Marti GE.
Albumin enhanced morphometric image analysis in CLL.
Cytometry B Clin Cytom. 57: 7-14, 2004.
128)  Grube M, Rezvani K, Wiestner A, Fujiwara H, Sconocchia G, Melenhorst JJ, Hensel N, Marti GE, Kwak LW, Wilson W, Barrett JA.
Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
Clin. Cancer Res. 10: 1047-56, 2004.
129)  Janik JE, Morris JC, Pittaluga S, McDonald K, Raffeld M, Jaffe ES, Grant N, Gutierrez M, Waldmann TA, Wilson WH.
Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Blood. 104: 3355-7, 2004.
130)  Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM.
Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Blood. 104: 1428-34, 2004.
131)  Leonard GD, Posadas E, Herrmann PC, Anderson VL, Jaffe ES, Holland SM, Wilson WH.
Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review.
Leuk. Lymphoma. 45: 2521-5, 2004.
132)  Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM.
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.
N. Engl. J. Med. 351: 2159-69, 2004.
133)  FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I.
Recombinant immunotoxins for treating cancer.
Int. J. Med. Microbiol. 293: 577-82, 2004.
134)  Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, Leitman SF, Bolan CD.
Transfusion medicine illustrated. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma.
Transfusion. 44: 1679, 2004.
135)  Mattu R, Sorbara L, Filie AC, Little R, Wilson W, Raffeld M, Abati A.
Utilization of polymerase chain reaction on archival cytologic material: a comparison with fresh material with special emphasis on cerebrospinal fluids.
Mod. Pathol. 17: 1295-301, 2004.
136)  Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH.
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Biol. Blood Marrow Transplant. 9: 162-9, 2003.
137)  Leonard GD, Hegde U, Butman J, Jaffe ES, Wilson WH.
Extraoular muscle palsies in subcutaneous panniculitis-like T-cell lymphoma.
J. Clin. Oncol. 21: 2993-5, 2003.
138)  Nguyen JD, Carrasquillo JA, Little RF, Ryan QC, Wilson W, Chen CC.
Fluorodeoxyglucose positron emission tomography in the presence of cardiac metastases.
Clinical nuclear medicine. 28: 979-80, 2003.
139)  Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH.
Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
Blood. 101: 4653-9, 2003.
140)  Bryant-Greenwood P, Sorbara L, Filie AC, Little R, Yarchoan R, Wilson W, Raffeld M, Abati A.
Infection of mesothelial cells with human herpes virus 8 in human immunodeficiency virus-infected patients with Kaposi's sarcoma, Castleman's disease, and recurrent pleural effusions.
Mod. Pathol. 16: 145-53, 2003.
141)  Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM.
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
J. Exp. Med. 198: 851-62, 2003.
142)  Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM.
The Proliferation Gene Expression Signature is a Quantitative Integrator of Oncogenic Events that Predicts Survival in Mantle Cell Lymphoma.
Cancer Cell. 3: 185, 2003.
143)  Little RF, Wilson WH.
Update on the Pathogenesis, Diagnosis, and Therapy of AIDS-related Lymphoma.
Curr Infect Dis Rep. 5: 176-184, 2003.
144)  Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
Blood. 101: 4944-51, 2003.
145)  Wilson W, Grossbard M, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg S, Little R, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson B, Longo D, Harris N, Jaffe E, Chabner B, Wittes R, Balis F.
Dose-adjusted EPOCH chemotherapy in untreated large B-cell lymphomas: A novel pharmacodynamic approach with high efficacy.
Blood. 99: 2685-2693, 2002.
146)  Staudt L, Wilson W.
Focus on lymphomas.
Cancer Cell. 2: 363-6, 2002.
147)  Hegde UP, Wilson WH, White T, Cheson BD.
Rituximab Treatment of Refractory Fludarabine-associated Immune Thrombocytopenia in Chronic Lymphocytic Leukemia.
Blood. 100: 2260, 2002.
148)  Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner BA, Grossbard ML.
Role of rituximab and chemotherapy in aggressive B-cell lymphomas: A preliminary report of dose-adjusted EPOCH-R.
Semin Oncol. 29: 41-47, 2002.
149)  Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM.
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
N. Engl. J. Med. 346: 1937-47, 2002.
150)  Beaty MW, Toro J, Sorbara L, Stern JB, Pittaluga S, Raffeld M, Wilson WH, Jaffe ES.
Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features.
Am. J. Surg. Pathol. 25: 1111-20, 2001.
151)  Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I.
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
N. Engl. J. Med. 345: 241-7, 2001.
152)  Hegde U, Wilson WH.
Gene expression profiling of lymphomas.
Current oncology reports. 3: 243-9, 2001.
153)  Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE.
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
Blood. 98: 2865-8, 2001.
154)  Saif MW, Little RF, Hamilton JM, Allegra CJ, Wilson WH.
Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature.
Ann. Oncol. 12: 123-9, 2001.
155)  Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM.
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
J. Exp. Med. 194: 1639-47, 2001.
156)  Bishop PC, Rao VK, Wilson WH.
Burkitt's lymphoma: molecular pathogenesis and treatment.
Cancer Invest. 18: 574-83, 2000.
157)  Wilson WH.
Chemotherapy sensitization by rituximab: experimental and clinical evidence.
Semin. Oncol. 27: 30-6, 2000.
158)  Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Cancer journal (Sudbury, Mass.). 6: 146-50, 2000.
159)  Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A.
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clin. Cancer Res. 6: 415-21, 2000.
160)  Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I.
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
J. Clin. Oncol. 18: 1622-36, 2000.
161)  Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH.
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
J. Clin. Oncol. 18: 3633-42, 2000.
162)  Little RF, Yarchoan R, Wilson WH.
Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy.
Current opinion in oncology. 12: 438-44, 2000.
163)  Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC.
CNS involvement in primary mediastinal large B-cell lymphoma.
J. Clin. Oncol. 17: 2479-85, 1999.
164)  Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, Pastan I.
Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Blood. 94: 3340-8, 1999.
165)  Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD, Humphrey R, Kohler DR, Elwood P.
Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
J. Clin. Oncol. 16: 2345-51, 1998.
166)  Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R.
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.
J. Clin. Oncol. 16: 1112-21, 1998.
167)  Weng DE, Wilson WH, Little R, Walsh TJ.
Successful medical management of isolated renal zygomycosis: case report and review.
Clin. Infect. Dis. 26: 601-5, 1998.
168)  Little R, Wittes RE, Longo DL, Wilson WH.
Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.
J. Clin. Oncol. 16: 584-8, 1998.
169)  Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT.
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
J. Clin. Oncol. 15: 3338-46, 1997.
170)  Wilson WH.
Chemotherapy for AIDS-related lymphomas.
N. Engl. J. Med. 337: 1172-3; author reply 1173-4, 1997.
171)  Molldrem J, Wilson WH.
Infusional chemotherapy for non-Hodgkin's lymphoma.
Cancer Invest. 15: 465-74, 1997.
172)  Jaffe ES, Wilson WH.
Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications.
Cancer Surv. 30: 233-48, 1997.
173)  Georgiadis MS, Schuler BS, Brown JE, Kieffer LV, Steinberg SM, Wilson WH, Takimoto CH, Kelley MJ, Johnson BE.
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.
J. Clin. Oncol. 15: 735-43, 1997.
174)  Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M.
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.
Blood. 89: 601-9, 1997.
175)  Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, Longo DL, Tosato G.
The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease.
Blood. 90: 4099-105, 1997.
176)  Prussick R, Horn TD, Wilson WH, Turner MC.
A characteristic eruption associated with ifosfamide, carboplatin, and etoposide chemotherapy after pretreatment with recombinant interleukin-1 alpha.
J. Am. Acad. Dermatol. 35: 705-9, 1996.
177)  Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES.
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b.
Blood. 87: 4531-7, 1996.
178)  .
Clinical Reversal of Multidrug Resistance.
Oncologist. 1: 269-275, 1996.
179)  Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B.
Clinical reversal of multidrug resistance.
Stem Cells. 14: 56-63, 1996.
180)  Cheson BD, Wilson WH, Phillips PH.
Clinical trials at the medicine branch of the NCI-part 2.
Oncology (Williston Park, N.Y.). 9: 506, 509-10, 1995.
181)  Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J.
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy.
J. Clin. Oncol. 13: 1995-2004, 1995.
182)  Wilson WH, Bates SE, Fojo A, Chabner BA.
Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas.
J. Cancer Res. Clin. Oncol. 121 Suppl 3: R25-9, 1995.
183)  Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE.
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
J. Clin. Oncol. 13: 1985-94, 1995.
184)  Wilson WH, Chabner BA, Bryant G, Bates S, Fojo A, Regis J, Jaffe ES, Steinberg SM, Goldspiel BR, Cheson BD.
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
J. Clin. Oncol. 13: 381-6, 1995.
185)  Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, Broder S.
Treatment of HIV-associated Kaposi's sarcoma with paclitaxel.
Lancet. 346: 26-8, 1995.
186)  Chabner BA, Bates SE, Fojo AT, Spolyar M, Wilson WH.
Drug resistance in adult lymphomas.
Semin. Hematol. 31: 70-87, 1994.
187)  Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J.
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
J. Clin. Oncol. 12: 1621-9, 1994.
188)  Wilson WH.
The role of GM-CSF and G-CSF in stem cell transplantation.
Oncology (Williston Park, N.Y.). 8: 17-8, 1994.
189)  Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD.
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
J. Clin. Oncol. 11: 1573-82, 1993.
190)  Quezado ZM, Wilson WH, Cunnion RE, Parker MM, Reda D, Bryant G, Ognibene FP.
High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.
Ann. Intern. Med. 118: 31-6, 1993.
191)  Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE.
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
J. Clin. Oncol. 10: 1712-22, 1992.
192)  Urba WJ, Wilson WH, Duffey PL, Wittes R, Chabner BA, Longo DL.
Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy.
Semin. Oncol. 19: 26-32, 1992.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/21/2014.